Claims
- 1. An isolated RIP-Thr514 polypeptide, comprising at least 10 consecutive amino acid residues of the amino acid sequence set forth as SEQ ID NO:2, which consecutive amino acid residues comprise the amino acid residue 514 (Thr) of SEQ ID NO:2.
- 2. An isolated polypeptide according to claim 1, wherein said polypeptide has an activity selected from at least one of: a kinase or kinase inhibitory activity or a RIP-binding or binding inhibitory activity.
- 3. An isolated or recombinant RIP-ACA1540-1542 nucleic acid comprising at least 24 consecutive nucleotides of the nucleotide sequence set forth as SEQ ID NO:1, which consecutive polynucleotides comprise the polynucleotides 1540-1542 (ACA) of SEQ ID NO:1.
- 4. A recombinant nucleic acid encoding a polypeptide according to claim 1.
- 5. A cell comprising a nucleic acid according to claim 4.
- 6. A method of making an isolated RIP polypeptide, said method comprising steps: introducing a nucleic acid according to claim 4 into a host cell or cellular extract, incubating said host cell or extract under conditions whereby said nucleic acid is expressed as a transcript and said transcript is expressed as a translation product comprising said polypeptide, and isolating said translation product.
- 7. A method of screening for an agent which modulates the interaction of a RIP polypeptide to a binding target, said method comprising the steps of:
incubating a mixture comprising:
an isolated polypeptide according to claim 1, a binding target of said polypeptide, and a candidate agent; under conditions whereby, but for the presence of said agent, said polypeptide specifically binds said binding target at a reference affinity; detecting the binding affinity of said polypeptide to said binding target to determine an agent-biased affinity, wherein a difference between the agent-biased affinity and the reference affinity indicates that said agent modulates the binding of said polypeptide to said binding target.
- 8. A method according to claim 7, wherein said binding target is a natural intracellular substrate and said reference and agent-biased binding affinity is detected as phosphorylation of said substrate.
- 9. A method according to claim 7, wherein said binding target comprises a Tumor necrosis factor receptor Associated Factor −2 (TRAF2) or a Tumor necrosis factor Receptor-1 Associated Death Domain protein (TRADD).
CROSS-REFERENCE TO RELATED APPLICATION
[0001] This is a continuing application under 35USC120 of U.S. patent application Ser. No. 08/553,727, filed Oct. 23, 1995.
Divisions (1)
|
Number |
Date |
Country |
Parent |
09132118 |
Aug 1998 |
US |
Child |
09758003 |
Jan 2001 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
08553727 |
Oct 1995 |
US |
Child |
09132118 |
Aug 1998 |
US |